Avelumab in gastric cancer

Giandomenico Roviello; Alberto D'Angelo; Daniele Generali; Matteo Pittacolo; Monica Ganzinelli; Giandomenica Iezzi; Nicolò de Manzini; Navid Sobhani

doi:10.2217/imt-2019-0011

Avelumab in gastric cancer

Giandomenico Roviello, Alberto D'Angelo, Daniele Generali, Matteo Pittacolo, Monica Ganzinelli, Giandomenica Iezzi, Nicolò de Manzini, Navid Sobhani

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

15 Citations (SciVal)

64 Downloads (Pure)

Abstract

Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

Original language	English
Pages (from-to)	759-768
Number of pages	10
Journal	Immunotherapy
Volume	11
Issue number	9
Early online date	6 May 2019
DOIs	https://doi.org/10.2217/imt-2019-0011
Publication status	Published - 16 May 2019

Keywords

avelumab
gastric cancer
immunotherapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/imt-2019-0011

10.2217_imt_2019_0011.pdf
This is the author accepted manuscript of a paper published as Roviello, G, D'Angelo, A, Generali, D, Pittacolo, M, Ganzinelli, M, Iezzi, G, Manzini, ND & Sobhani, N 2019, 'Avelumab in gastric cancer', Immunotherapy, vol. 11, no. 9, pp. 759-768 and available online via: https://doi.org/10.2217/imt-2019-0011
Accepted author manuscript, 980 KB

Cite this

@article{c9aec0b8563b436a982de17fbac4efc8,

title = "Avelumab in gastric cancer",

abstract = "Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.",

keywords = "avelumab, gastric cancer, immunotherapy",

author = "Giandomenico Roviello and Alberto D'Angelo and Daniele Generali and Matteo Pittacolo and Monica Ganzinelli and Giandomenica Iezzi and Manzini, {Nicol{\`o} de} and Navid Sobhani",

year = "2019",

month = may,

day = "16",

doi = "10.2217/imt-2019-0011",

language = "English",

volume = "11",

pages = "759--768",

journal = "Immunotherapy",

issn = "1750-7448",

publisher = "Future Medicine",

number = "9",

}

TY - JOUR

T1 - Avelumab in gastric cancer

AU - Roviello, Giandomenico

AU - D'Angelo, Alberto

AU - Generali, Daniele

AU - Pittacolo, Matteo

AU - Ganzinelli, Monica

AU - Iezzi, Giandomenica

AU - Manzini, Nicolò de

AU - Sobhani, Navid

PY - 2019/5/16

Y1 - 2019/5/16

N2 - Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

AB - Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

KW - avelumab

KW - gastric cancer

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85066042477&partnerID=8YFLogxK

U2 - 10.2217/imt-2019-0011

DO - 10.2217/imt-2019-0011

M3 - Article

C2 - 31060469

SN - 1750-7448

VL - 11

SP - 759

EP - 768

JO - Immunotherapy

JF - Immunotherapy

IS - 9

ER -

Avelumab in gastric cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this